| James Simeon Adams Neill, MD | |
|
106 Easthaven Dr, Brandon, MS 39042-2825 | |
| (601) 984-1530 | |
| (601) 984-1531 |
| Full Name | James Simeon Adams Neill |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 46 Years |
| Location | 106 Easthaven Dr, Brandon, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912987819 | NPI | - | NPPES |
| 06172073 | Medicaid | MS | |
| P01402418 | Other | MS | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 08398 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Merit Health Women's Hospital | Flowood, MS | Hospital |
| Merit Health River Region | Vicksburg, MS | Hospital |
| Merit Health Wesley | Hattiesburg, MS | Hospital |
| Merit Health Madison | Canton, MS | Hospital |
| Merit Health River Oaks | Flowood, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hub Care Pathology, P.a. | 3173616240 | 9 |
News Archive
New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of Health Care Reforms in India: Making Up for the Lost Decade, an authoritative and incisive look at India's healthcare system from the perspective of Rajendra Pratap Gupta, an expert healthcare observer as well as an influential and respected voice on public policy, innovation and the economy.
U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports.
Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.
› Verified 9 days ago
| Entity Name | Hub Care Pathology, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043324767 PECOS PAC ID: 3173616240 Enrollment ID: O20070905000545 |
News Archive
New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of Health Care Reforms in India: Making Up for the Lost Decade, an authoritative and incisive look at India's healthcare system from the perspective of Rajendra Pratap Gupta, an expert healthcare observer as well as an influential and respected voice on public policy, innovation and the economy.
U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports.
Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.
› Verified 9 days ago
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of Health Care Reforms in India: Making Up for the Lost Decade, an authoritative and incisive look at India's healthcare system from the perspective of Rajendra Pratap Gupta, an expert healthcare observer as well as an influential and respected voice on public policy, innovation and the economy.
U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports.
Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Simeon Adams Neill, MD 106 Easthaven Dr, Brandon, MS 39042-2825 Ph: (601) 984-1530 | James Simeon Adams Neill, MD 106 Easthaven Dr, Brandon, MS 39042-2825 Ph: (601) 984-1530 |
News Archive
New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of Health Care Reforms in India: Making Up for the Lost Decade, an authoritative and incisive look at India's healthcare system from the perspective of Rajendra Pratap Gupta, an expert healthcare observer as well as an influential and respected voice on public policy, innovation and the economy.
U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports.
Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.
› Verified 9 days ago